Use of Oral Anticoagulant Drugs in Patients with Pulmonary Hypertension
Heart Failure Clinics, ISSN: 1551-7136, Vol: 19, Issue: 1, Page: 97-106
2023
- 2Citations
- 9Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations2
- Citation Indexes2
- Captures9
- Readers9
Review Description
Pulmonary hypertension (PH), in particular pulmonary arterial hypertension and chronic thromboembolic PH, burdens patients with relevant morbidity and mortality. The use of oral anticoagulants (OACs) seems able to mitigate the risk of adverse outcomes and death in these patients. Despite scarce evidence, the use of OAC is recommended to treat PH patients, mainly based on observational data. So far, data are still unclear about the impact of direct oral anticoagulant (DOACs), whereas vitamin K antagonists are the main drugs recommended. More data are needed to fully clarify the role of OAC and DOACs in PH patients.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1551713622000708; http://dx.doi.org/10.1016/j.hfc.2022.08.018; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85142940176&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36435577; https://linkinghub.elsevier.com/retrieve/pii/S1551713622000708; https://dx.doi.org/10.1016/j.hfc.2022.08.018
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know